Immune activation in α1-antitrypsin-deficiency emphysema: Beyond the protease-antiprotease paradigm

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 4, 2015, Pages 402-409

  Baraldo, Simonetta ^a   Turato, Graziella ^a   Lunardi, Francesca ^a   Bazzan, Erica ^a   Schiavon, Marco ^a   Ferrarotti, Ilaria ^b   Molena, Beatrice ^a   Cazzuffi, Riccardo ^a   Damin, Marco ^a   Balestro, Elisabetta ^a   Luisetti, Maurizio ^b   Rea, Federico ^a   Calabrese, Fiorella ^a   Cosio, Manuel G ^a,c   Saetta, Marina ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Autoimmunity; Chronic obstructive pulmonary disease; Lymphocytes; Lymphoid follicles; 1 antitrypsin

Indexed keywords

ALPHA 1 ANTITRYPSIN; CD4 ANTIGEN; CD8 ANTIGEN; DNA; INTERLEUKIN 32; PANCREATIC ELASTASE; SERINE PROTEINASE INHIBITOR;

ADAPTIVE IMMUNITY; ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; LUNG EMPHYSEMA; LUNG FUNCTION; LYMPH FOLLICLE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; COMPLICATION; ENZYMOLOGY; IMMUNOLOGY; MIDDLE AGED;

ADAPTIVE IMMUNITY; ALPHA 1-ANTITRYPSIN DEFICIENCY; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC ELASTASE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; SERINE PROTEINASE INHIBITORS;

EID: 84922895336     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201403-0529OC     Document Type: Article

References (40)

1. Laurell CB, Eriksson S. The electrophoretic a1-globulin pattern of serum in a1-antitrypsin deficiency. Scand J Clin Lab Invest 1963;15: 132-140.
2. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z a1-antitrypsin accumulation in the liver. Nature 1992;357:605-607.
3. Carp H, Miller F, Hoidal JR, Janoff A. Potential mechanism of emphysema: a 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci USA 1982;79:2041-2045.
4. Demeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax 2007;62:806-813.
5. Bergin DA, Hurley K, McElvaney NG, Reeves EP. Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent. Arch Immunol Ther Exp (Warsz) 2012;60:81-97.
6. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009;360:2445-2454.
7. Baraldo S, Bazzan E, Turato G, Molena B, Lunardi F, Nannini N, Damin M, Schiavon M, Balestro E, Loy M, et al. Similar adaptive immune response in COPD patients with and without a1 antitrypsin deficiency [abstract 2739]. Eur Respir J 2013;42(Suppl 57):599.
8. Calabrese F, Nannini N, Lunardi F, Baraldo S, Bazzan E, Balestro E, Schiavon M, Rea F, Saetta M. Adaptive immune response in COPD patients with and without a-1 antitrypsin deficiency [ESP Abstracts 2013]. Virchows Arch 2013;463:245.
9. Bazzan E, Baraldo S, Lunardi F, Lokar Oliani K, Ballarin A, Schiavon M, Turato G, Balestro E, Rea F, Loy M, et al. Immune activation in a1 antitrypsin deficiency (AATD) emphysema: beyond the protease/ antiprotease hypothesis [abstract 3047]. Eur Respir J 2012;40 (Suppl 56):827s.
10. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp CE, Maestrelli P, et al. CD81ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:711-717.
11. Heard BE. A pathological study of emphysema of the lungs with chronic bronchitis. Thorax 1958;13:136-149.
12. Hsia CC, Hyde DM, Ochs M, Weibel ER; ATS/ERS Joint Task Force on Quantitative Assessment of Lung Structure. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 2010;181:394-418.
13. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G, Lokar-Oliani K, Papi A, Zuin R, et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:894-901.
14. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
15. Carroll TP, Greene CM, O'Connor CA, Nolan AM, O'Neill SJ, McElvaney NG. Evidence for unfolded protein response activation in monocytes from individuals with a-1 antitrypsin deficiency. J Immunol 2010;184:4538-4546.
16. Low TB, Greene CM, O'Neill SJ, McElvaney NG. Quantification and evaluation of the role of antielastin autoantibodies in the emphysematous lung. Pulm Med 2011;2011:826160.
17. Polverino F, Baraldo S, Bazzan E, Agostini S, Turato G, Lunardi F, Balestro E, Damin M, Papi A, Maestrelli P, et al. A novel insight into adaptive immunity in chronic obstructive pulmonary disease: B cell activating factor belonging to the tumor necrosis factor family. Am J Respir Crit Care Med 2010;182:1011-1019.
18. van de Pavert SA, Mebius RE. New insights into the development of lymphoid tissues. Nat Rev Immunol 2010;10:664-674.
19. van der Strate BW, Postma DS, Brandsma CA, Melgert BN, Luinge MA, Geerlings M, Hylkema MN, van den Berg A, Timens W, Kerstjens HA. Cigarette smoke-induced emphysema: A role for the B cell? Am J Respir Crit Care Med 2006;173:751-758.
20. Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough JE, Gosselink JV, Cooper J, Sin DD, Mohn WW, Hogg JC. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1073-1080.
21. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, Young VB, Toews GB, Curtis JL, Sundaram B, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS ONE 2011;6:e16384.
22. Dickson RP, Huang YJ, Martinez FJ, Huffnagle GB. The lung microbiome and viral-induced exacerbations of chronic obstructive pulmonary disease: new observations, novel approaches. Am J Respir Crit Care Med 2013;188:1185-1186.
23. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW, Csizmadia E, Zhang Y, Sciurba FC, Duncan SR. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:156-163.
24. Duncan SR. The missing link between smoking and COPD autoreactivity? Am J Respir Crit Care Med 2011;184:747-749.
25. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006;24:467-496.
26. Sullivan AK, Simonian PL, Falta MT, Mitchell JD, Cosgrove GP, Brown KK, Kotzin BL, Voelkel NF, Fontenot AP. Oligoclonal CD41 T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med 2005;172:590-596.
27. Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007;13:567-569.
28. Motz GT, Eppert BL, Wesselkamper SC, Flury JL, Borchers MT. Chronic cigarette smoke exposure generates pathogenic T cells capable of driving COPD-like disease in Rag2-/- mice. Am J Respir Crit Care Med 2010;181:1223-1233.
29. Maeno T, Houghton AM, Quintero PA, Grumelli S, Owen CA, Shapiro SD. CD81 T Cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J Immunol 2007;178:8090-8096.
30. Cosio MG, Saetta M. Evasion of COPD in smokers: at what price? Eur Respir J 2012;39:1298-1303.
31. Stockley RA. a1-antitrypsin deficiency: what has it ever done for us? Chest 2013;144:1923-1929.
32. Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Köhnlein T, Welte T. The discovery of a1-antitrypsin and its role in health and disease. Respir Med 2011;105:1129-1139.
33. Breit SN, Wakefield D, Robinson JP, Luckhurst E, Clark P, Penny R. The role of a 1-antitrypsin deficiency in the pathogenesis of immune disorders. Clin Immunol Immunopathol 1985;35:363-380.
34. Marcondes AM, Li X, Tabellini L, Bartenstein M, Kabacka J, Sale GE, Hansen JA, Dinarello CA, Deeg HJ. Inhibition of IL-32 activation by a-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood 2011;118: 5031-5039.
35. Bergin DA, Reeves EP, Hurley K, Wolfe R, Jameel R, Fitzgerald S, McElvaney NG. The circulating proteinase inhibitor a-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med 2014;6:217ra1.
36. Wood AM, Needham M, Simmonds MJ, Newby PR, Gough SC, Stockley RA. Phenotypic differences in alpha 1 antitrypsindeficient sibling pairs may relate to genetic variation. COPD 2008;5:353-359.
37. Taggart C, Cervantes-Laurean D, Kim G, McElvaney NG, Wehr N, Moss J, Levine RL. Oxidation of either methionine 351 or methionine 358 in a 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem 2000;275:27258-27265.
38. Moraga F, Janciauskiene S. Activation of primary human monocytes by the oxidized form of a1-antitrypsin. J Biol Chem 2000;275: 7693-7700.
39. Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in a1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med 2004;170:1172-1178.
40. Piras B, Ferrarotti I, Lara B, Martinez MT, Bustamante A, Ottaviani S, Pirina P, Luisetti M, Miravitlles M. Clinical phenotypes of Italian and Spanish patients with a1-antitrypsin deficiency. Eur Respir J 2013; 42:54-64.